Loading...
•
Mar 31, 2022
Evelo Q1 2022 Earnings Report
Reported positive data for EDP1815 in psoriasis and advanced EDP1815 towards later-stage clinical trials.
Key Takeaways
Evelo Biosciences reported first quarter 2022 financial results, highlighting positive data for EDP1815 in psoriasis and the advancement of EDP1815 towards later-stage clinical trials. The company's cash and cash equivalents were $39.6 million as of March 31, 2022.
Reported positive data for EDP1815 in psoriasis, demonstrating effects on systemic inflammatory cytokine markers.
Showed depth and duration of response at 6-month follow-up post dosing for EDP1815 in psoriasis.
Observed increased target site engagement with a faster release capsule for EDP1815 in psoriasis.
Recruitment is ahead of plan in Phase 2 trial of EDP1815 in atopic dermatitis, with data expected in Q1 and Q2 2023.
Evelo
Evelo
Forward Guidance
Evelo Biosciences anticipates data from the first 3 cohorts of the Phase 2 atopic dermatitis trial in mild, moderate, and severe atopic dermatitis in 1Q 2023, with data from a potential additional fourth cohort anticipated in 2Q 2023. The company also plans to initiate clinical development of EDP2939 in 3Q 2022 and expects Phase 2 data from a cohort of patients with psoriasis in 2H 2023.
Positive Outlook
- Anticipates data from the first 3 cohorts of the Phase 2 atopic dermatitis trial in 1Q 2023.
- Potential data from a fourth cohort in the Phase 2 atopic dermatitis trial anticipated in 2Q 2023.
- Plans to initiate clinical development of EDP2939 in 3Q 2022.
- Expects Phase 2 data from a cohort of patients with psoriasis in 2H 2023.